Loading company…
RECORNA develops targeted RNA editing technologies and drugs.
Founded in 2021 and based in Guangzhou, RECORNA develops targeted RNA editing technologies and drugs for cardiovascular, neurological, respiratory, and other diseases. Its research platforms include drug discovery, biological validation, and delivery system development. In April 2025, the company raised venture funding from Huangpu Biomedical Investment and Oriental Fortune Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in